ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1685

IL2 Decrease Is Associated to ANTI-DNA Positivity in Systemic LUPUS Erythematous Patients

Elena Grau Garcia1, Francisco Miguel Ortiz-Sanjuán1, Cristina Alcañiz Escandell1, Karla Arevalo Ruales1, Inmaculada Chalmeta Verdejo1, Marta De la Rubia Navarro1, Jorge Juan Fragio Gil1, Roxana Gonzalez Mazario1, Luis Gonzalez Puig1, Jose Ivorra Cortes1, Isabel Martinez Cordellat1, Rosa Negueroles Albuixech1, Jose Eloy Oller Rodriguez1, Elvira Vicens Bernabeu1, Carmen Najera Herranz1, Ines Canovas Olmos1, David Hervás Marín2, Meritxel Fernandez Matilla3, Nagore Fernandez-Llanio Cornella3, Jose Antonio Castellano Cuesta3, Cristobal Antonio Pavez Perales1 and Jose Andres Roman Ivorra1, 1Rheumatology Department. Hospital Universitario y Politecnico La Fe, Valencia, Spain, 2Biostatistics Unit. IIS La Fe, Valencia, Spain, 3Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: ,

Session Information

Date: Monday, October 22, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease characterized by deregulation of cytokine production. IL2 is an anti-inflammatory cytokine in SLE, but its loss leads to the Th2 system activation and in consequence, Th2 proinflammatory cytokines as IL10 are produced. The aim is to analyze the association between IL2 serum levels and clinical activity in SLE. The secondary objective is to characterize the correlation between IL2 and IL10 serum levels.

Methods: A cross-sectional, observational study of 142 patients diagnosed of SLE (according to SLICC 2012 criteria), and 35 healthy controls, was performed. A complete blood-test and an interview were carried out to collect their clinical data. We analyzed IL2 and IL10 serum levels by colorimetric methods. SLE patients were dichotomized as high and low levels for IL2 based on the 5% and 95% percentile values in healthy controls. Biostatistical analysis with R was performed.

Results:

142 SLE patients were evaluated; 94.4% of them were female. Mean values were as follow: age at diagnosis 33.29±13.53 years, disease duration 15.82±10.56 years, SLEDAI 5.91±5.06, IL2 levels 4.34 ±12.2 ng/mL and IL10 levels 12.29 ± 32.82 ng/mL.

We observed lower values of IL2 in SLE patients than in healthy controls (P=0.002), and higher values of IL10 in SLE patients than in healthy controls (P<0.001). Statistical analysis indicates that decreased levels of IL2 is associated with anti-DNA positivity (P=0.045). We did not observe a statistically significant association between IL2 serum levels and SLEDAI scores or complement consumption.

Due to this finding, we categorized SLE patients by low IL2 levels (n=37), normal IL2 levels (n=98) and high IL2 levels (n=7).

IL2 high levels

(n = 7)

Mean (SD)

IL2 normal levels

(n = 98)

Mean (SD)

IL2 low levels

(n = 37)

Mean (SD)

IL2 levels (ng/mL)

40.05 (41.08)

3.37 (3.52)

0.16 (0.08)

Anti-dsDNA (ng/mL)

12.63 (15.49)

27.49 (57.84)

35.31 (63.12)

C3 (ng/mL)

103.71 (40.13)

107.46 (28.77)

107.89 (24.27)

C4 (ng/mL)

15.86 (6.72)

18 (9.05)

18.35 (8.1)

SLEDAI

7.29 (5.68)

5.63 (5.12)

6.38 (4.82)

The statistical analysis did not yield differences in the clinical activity, anti-DNA or C3-C4 serum levels among patients with lower, normal and higher IL2 levels.Despite the fact that no specific IL2 profile associated with clinical activity was observed, those patients with low IL2 profile had increased anti-DNA levels.

Conclusion: In our series, we observed a decrease in IL2 levels and an increase of IL10 levels, according to the production of the Th2 proinflammatory cytokines in IL2 low levels context. We noted a statically significant association between low IL2 levels and anti-DNA high levels. We have found no statistical evidences on the relationship of IL2 levels and clinical activity in our series of patients.

Disclosure: E. Grau Garcia, None; F. M. Ortiz-Sanjuán, None; C. Alcañiz Escandell, None; K. Arevalo Ruales, None; I. Chalmeta Verdejo, None; M. De la Rubia Navarro, None; J. J. Fragio Gil, None; R. Gonzalez Mazario, None; L. Gonzalez Puig, None; J. Ivorra Cortes, None; I. Martinez Cordellat, None; R. Negueroles Albuixech, None; J. E. Oller Rodriguez, None; E. Vicens Bernabeu, None; C. Najera Herranz, None; I. Canovas Olmos, None; D. Hervás Marín, None; M. Fernandez Matilla, None; N. Fernandez-Llanio Cornella, None; J. A. Castellano Cuesta, None; C. A. Pavez Perales, None; J. A. Roman Ivorra, None.

To cite this abstract in AMA style:

Grau Garcia E, Ortiz-Sanjuán FM, Alcañiz Escandell C, Arevalo Ruales K, Chalmeta Verdejo I, De la Rubia Navarro M, Fragio Gil JJ, Gonzalez Mazario R, Gonzalez Puig L, Ivorra Cortes J, Martinez Cordellat I, Negueroles Albuixech R, Oller Rodriguez JE, Vicens Bernabeu E, Najera Herranz C, Canovas Olmos I, Hervás Marín D, Fernandez Matilla M, Fernandez-Llanio Cornella N, Castellano Cuesta JA, Pavez Perales CA, Roman Ivorra JA. IL2 Decrease Is Associated to ANTI-DNA Positivity in Systemic LUPUS Erythematous Patients [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/il2-decrease-is-associated-to-anti-dna-positivity-in-systemic-lupus-erythematous-patients/. Accessed .

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il2-decrease-is-associated-to-anti-dna-positivity-in-systemic-lupus-erythematous-patients/